Focused Ultrasound for Neurodegeneration

Focused Ultrasound for Neurodegeneration

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Focused Ultrasound for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Condition</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Parkinson's Disease (tremor)</td>
<td>VIM thalamus</td>
</tr>
<tr>
<td class="label">Parkinson's Disease (bradykinesia)</td>
<td>STN, GPi</td>
</tr>
<tr>
<td class="label">Essential Tremor</td>
<td>VIM thalamus</td>
</tr>
<tr>
<td class="label">Dystonia</td>
<td>GPi, STN</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">FUS + Anti-amyloid antibodies</td>
<td>Enhanced Aβ clearance</td>
</tr>
<tr>
<td class="label">FUS + Chemotherapy</td>
<td>Better brain tumor delivery</td>
</tr>
<tr>
<td class="label">FUS + Gene therapy</td>
<td>AAV delivery across BBB</td>
</tr>
<tr>
<td class="label">FUS + Immunotherapy</td>
<td>Enhanced CNS immune response</td>
</tr>
</table>

Focused Ultrasound For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Focused Ultrasound for Neurodegeneration

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Focused Ultrasound for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Condition</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Parkinson's Disease (tremor)</td>
<td>VIM thalamus</td>
</tr>
<tr>
<td class="label">Parkinson's Disease (bradykinesia)</td>
<td>STN, GPi</td>
</tr>
<tr>
<td class="label">Essential Tremor</td>
<td>VIM thalamus</td>
</tr>
<tr>
<td class="label">Dystonia</td>
<td>GPi, STN</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">FUS + Anti-amyloid antibodies</td>
<td>Enhanced Aβ clearance</td>
</tr>
<tr>
<td class="label">FUS + Chemotherapy</td>
<td>Better brain tumor delivery</td>
</tr>
<tr>
<td class="label">FUS + Gene therapy</td>
<td>AAV delivery across BBB</td>
</tr>
<tr>
<td class="label">FUS + Immunotherapy</td>
<td>Enhanced CNS immune response</td>
</tr>
</table>

Focused Ultrasound For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Focused Ultrasound (FUS) is a non-invasive therapeutic technology that uses acoustic energy to precisely target brain regions for treatment of neurodegenerative diseases. It offers a unique combination of thermal ablation, [blood-brain barrier](/entities/blood-brain-barrier) (BBB) opening, and neuromodulation without surgical intervention. [@focused2020]

Technology Platforms

High-Intensity Focused Ultrasound (HIFU)

• Mechanism: Thermal ablation through focused acoustic energy
• Applications: Thalamotomy for tremor, target ablation in movement disorders
• FDA Approved: Essential tremor, Parkinson's disease tremor

Low-Intensity Focused Ultrasound (LIFU/LIFUS)

• Mechanism: Neuromodulation without tissue heating
• Applications: Non-invasive brain stimulation
• Research Stage: Clinical trials ongoing

Focused Ultrasound with Microbubbles (FUS-BBBO)

• Mechanism: Acoustic cavitation opens blood-brain barrier
• Applications: Drug delivery, biomarker release
• Clinical Trials: AD, PD, ALS

Clinical Applications

Movement Disorders

Alzheimer's Disease

Other Neurodegenerative Conditions

• Amyotrophic Lateral Sclerosis (ALS): Motor [cortex](/brain-regions/cortex) application
• Multiple Sclerosis: Myelin repair enhancement
• Brain Tumors: Drug delivery enhancement

Mechanism of Action

Thermal Effects (HIFU)

• Protein denaturation at temperatures >55°C
• Coagulation necrosis of targeted tissue
• Precise lesioning with sub-millimeter accuracy

BBB Opening (FUS-BBBO)

• Transient opening of endothelial tight junctions
• Enhanced delivery of therapeutic agents
• Duration: 4-6 hours typically
• Repeat treatments possible

Neuromodulation (LIFU)

• Neuronal excitation or inhibition
• Modulation of neural circuits
• Non-invasive alternative to DBS

Clinical Evidence

Essential Tremor

• Phase III Trial: 76% tremor reduction at 1 year
• FDA Approval: 2016 for essential tremor
• Durability: Sustained benefit through 5 years

Parkinson's Disease Tremor

• Phase III Trial: Significant OFF-medication tremor reduction
• Motor Complications: Improved quality of life
• Comparison: Non-inferior to DBS in selected patients

Alzheimer's Disease (FUS-BBBO)

• Phase I Trial: Safe BBB opening, reduced [Aβ](/proteins/amyloid-beta) plaques
• Phase II Trial: Improved cognition with anti-amyloid antibodies
• Ongoing: Multi-center trials

Treatment Procedure

Pre-Treatment

During Treatment

Post-Treatment

Combination Therapies

Safety Profile

Common Adverse Events

• Headache (transient)
• Dizziness
• Mild confusion
• Scalp discomfort

Rare Complications

• Intracranial hemorrhage
• Thermal injury to off-target tissue
• Permanent neurological deficits (<1%)
• Edema at treatment site

Contraindications

• Metallic implants in treatment path
• Uncontrolled hypertension
• Coagulopathy
• Pregnancy

Background

The study of Focused Ultrasound For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

See Also

• [Deep Brain Stimulation](/technologies/deep-brain-stimulation)
• [Blood-Brain Barrier](/entities/blood-brain-barrier)
• [Essential Tremor](/diseases/essential-tremor)
• [Parkinson's Disease Treatment](/therapeutics/parkinsons-disease-treatment)
• Alzheimer's Disease Biomarkers

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
• [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
• [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
• [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
• [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7

Related Analyses:

• [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) &#x1f504;
• [SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) &#x1f504;
• [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) &#x1f504;
• [Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;